Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C
暂无分享,去创建一个
A. Wiczkowski | J. Kasperczyk | A. Gabriel | M. Kukla | R. Bułdak | T. Sawczyn | B. Adamek | D. Stygar | B. Sobala-Szczygieł | Marzena Zalewska-Ziob | Marta Stachowska
[1] W. Hung,et al. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection , 2017, Cytokine.
[2] G. Ippolito,et al. Hepatitis C virus relies on lipoproteins for its life cycle. , 2016, World journal of gastroenterology.
[3] G. Waris,et al. The Hepatitis C Virus-induced NLRP3 Inflammasome Activates the Sterol Regulatory Element-binding Protein (SREBP) and Regulates Lipid Metabolism* , 2015, The Journal of Biological Chemistry.
[4] Nadia Raffaelli,et al. Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues. , 2015, Biochimica et biophysica acta.
[5] R. Gebhardt,et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. , 2015, Biochemical and biophysical research communications.
[6] E. Jabłonowska,et al. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. , 2014, World journal of gastroenterology.
[7] H. Wee,et al. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer , 2014, Oncotarget.
[8] Zhongjie Sun,et al. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. , 2013, Cytokine & growth factor reviews.
[9] Shaojuan Lai,et al. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients , 2013, European journal of gastroenterology & hepatology.
[10] C. Richart,et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. , 2013, Clinical biochemistry.
[11] Z. Halpern,et al. The metabolic regulator PGC-1α links hepatitis C virus infection to hepatic insulin resistance. , 2012, Journal of hepatology.
[12] A. Gabriel,et al. Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[13] M. Kukla,et al. Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis , 2011, Molecular medicine.
[14] Ming‐Lung Yu,et al. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection , 2011, Journal of gastroenterology and hepatology.
[15] M. Kukla,et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. , 2011, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[16] A. Baranova,et al. Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C , 2010, Digestion.
[17] K. Koike,et al. Lipid Metabolism and Liver Disease in Hepatitis C Viral Infection , 2010, Oncology.
[18] A. Gabriel,et al. Visfatin serum levels in chronic hepatitis C patients , 2010, Journal of viral hepatitis.
[19] Qibin Zhang,et al. Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics , 2010, PLoS pathogens.
[20] J. D. del Campo,et al. Steatosis and insulin resistance in hepatitis C: a way out for the virus? , 2009, World journal of gastroenterology.
[21] A. Körner,et al. Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.
[22] H. Wee,et al. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. , 2009, Biochemical and biophysical research communications.
[23] T. Asselah,et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. , 2008, Gastroenterology.
[24] Ding‐Shinn Chen,et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[25] J. Milbrandt,et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. , 2007, Cell metabolism.
[26] M. Matsuda,et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. , 2007, Biochemical and biophysical research communications.
[27] Kyu-Won Kim,et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. , 2007, Biochemical and biophysical research communications.
[28] M. Elisaf,et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome , 2007, Journal of endocrinological investigation.
[29] Bounleut Phanavanh,et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. , 2007, The Journal of clinical endocrinology and metabolism.
[30] F. Negro. Mechanisms and significance of liver steatosis in hepatitis C virus infection. , 2006, World journal of gastroenterology.
[31] S. Eom,et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. , 2006, Journal of molecular biology.
[32] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[33] V. Pazienza,et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. , 2005, Journal of hepatology.
[34] K. Koike,et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.
[35] D. Gigot,et al. Pre‐B‐cell colony‐enhancing factor, whose expression is up‐regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis , 2002, European journal of immunology.
[36] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[37] I McNiece,et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor , 1994, Molecular and cellular biology.
[38] F. Zoulim,et al. HCV Virology , 2021, Hepatitis C: Epidemiology, Prevention and Elimination.
[39] A. Craxì,et al. Extrahepatic Manifestations of Chronic HCV , 2012 .
[40] W. Kiess,et al. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. , 2009, Frontiers in bioscience.
[41] Keiji Tanaka,et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. , 2003, Journal of virology.
[42] E. Bonora,et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.
[43] P. Scheuer,et al. The nomenclature of chronic hepatitis: time for a change. , 1995, Journal of hepatology.